Home » Stocks » ReShape Lifesciences

ReShape Lifesciences Inc. (RSLS)

Stock Price: $2.85 USD -0.15 (-5.00%)
Updated Aug 10, 2020 4:00 PM EDT - End of day

Stock Price Chart

Key Info

Market Cap 15.61M
Revenue (ttm) 14.80M
Net Income (ttm) -74.04M
Shares Out 5.48M
EPS (ttm) -21.61
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 10, 2020
Last Price $2.85
Previous Close $3.00
Change ($) -0.15
Change (%) -5.00%
Day's Open 3.14
Day's Range 2.85 - 3.14
Day's Volume 100
52-Week Range 1.14 - 14.25

More Stats

Market Cap 15.61M
Enterprise Value 16.91M
Earnings Date (est) Nov 11, 2020
Ex-Dividend Date n/a
Shares Outstanding 5.48M
Float 175,556
EPS (basic) -64.64
EPS (diluted) -21.61
FCF / Share -1.71
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short n/a
Short Ratio n/a
Short % of Float n/a
Beta 1.32
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 1.05
PB Ratio 0.72
Revenue 14.80M
Operating Income -24.30M
Net Income -74.04M
Free Cash Flow -11.76M
Net Cash -1.30M
Net Cash / Share -0.24
Gross Margin 62.85%
Operating Margin -164.12%
Profit Margin -500.10%
FCF Margin -79.44%
ROA -21.66%
ROE -295.33%
ROIC n/a
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (0)

Buy 0
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: n/a

Price Target

$537,600*
Low
537,600
Current: $2.85
High
537,600
Target: 537,600
*Average 12-month price target from 1 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue15.090.610.570.790.29--0.31--
Revenue Growth2385.83%6.65%-27.65%169.4%------
Gross Profit9.310.440.240.360.17--0.08--
Operating Income-24.46-38.55-28.05-22.80-27.87-25.59-24.73-22.55-25.26-16.18
Net Income-74.21-81.15-33.82-23.36-25.50-26.13-25.78-23.46-26.00-17.35
Shares Outstanding1.730.01--------
Earnings Per Share-42.93-9,023.14-773,439.38-9,464,657.36-75,396,978.69-101,947,448.35-124,065,042.29-156,176,490.50-227,647,087.85-545,294,187.18
Operating Cash Flow-14.20-27.49-24.59-20.66-22.61-19.38-18.43-22.48-19.94-13.66
Capital Expenditures-0.01-0.05-0.14-0.01-0.04-0.09-0.42-0.08-0.25-
Free Cash Flow-14.21-27.54-24.73-20.67-22.64-19.47-18.84-22.56-20.19-13.67
Cash & Equivalents2.995.5510.163.317.9311.6223.3022.5129.6937.37
Total Debt3.50---1.272.986.879.685.195.91
Net Cash / Debt-0.515.5510.163.316.668.6416.4312.8224.5031.46
Assets39.6646.2788.707.0411.5914.3926.3926.1032.4938.69
Liabilities15.5514.6112.344.107.917.7211.7114.2212.448.98
Book Value24.1131.6676.372.943.676.6614.6811.8720.0429.71
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name ReShape Lifesciences Inc.
Country United States
Employees 38
CEO Barton P. Bandy

Stock Information

Ticker Symbol RSLS
Stock Exchange US OTC
Unique Identifier OTCMKTS: RSLS
IPO Date November 15, 2007

Description

ReShape Lifesciences Inc., a medical device company, focuses on the design, development, and commercialization of technology to treat obesity and metabolic diseases. The company's product portfolio includes Lap-Band System, a minimally invasive long-term treatment of severe obesity and more invasive surgical stapling procedures, such as the gastric bypass or sleeve gastrectomy; and ReShape Vest system, an investigational, minimally invasive, laparoscopically implanted medical device that wraps around the stomach to enable weight loss in morbidly obese patients without permanently cutting or permanently removing portions of the stomach, or bypassing any portion of the gastrointestinal tract. The company was formerly known as EnteroMedics Inc. and changed its name to ReShape Lifesciences Inc. in October 2017. ReShape Lifesciences Inc. was founded in 2002 and is headquartered in San Clemente, California.